Peringkat dalam Saham
#17262
Adagio Therapeutics, Inc., a biopharmaceutical firm in its clinical development... Adagio Therapeutics, Inc., a biopharmaceutical firm in its clinical development phase, operates within the United States, specializing in the discovery, progression, and marketing of antibody-derived solutions for infectious diseases. The company's leading drug candidate, ADG20 (adintrevimab), is a neutralizing antibody currently undergoing Phase 3 clinical investigation for both the management and prevention of coronavirus disease. Adagio Therapeutics maintains collaborative agreements with Adimab, LLC to facilitate the identification and enhancement of its exclusive antibodies. Furthermore, it partners with the Scripps Research Institute to conduct studies aimed at uncovering potential vaccine solutions for the prophylaxis, detection, or therapy of influenza or beta coronaviruses. Incorporated in 2020, the company's base of operations is in Waltham, Massachusetts.
Kapitalisasi Pasar
$257.19M
Perubahan (1 hari)
-0.78%
Perubahan (1 tahun)
-15.24%
Perdagangan Invivyd, Inc. (IVVD)
Harga IVVD dengan kapitalisasi pasar B
Kapitalisasi pasar dari Invivyd, Inc.(IVVD)
Kapitalisasi Pasar: $257.19M
Per September 2026, Invivyd, Inc. memiliki kapitalisasi pasar sebesar $257.19M. Ini menjadikan Invivyd, Inc. sebagai perusahaan 17262nd paling bernilai di dunia menurut data kami. Kapitalisasi pasar adalah nilai total saham beredar dari perusahaan publik dan biasanya digunakan untuk mengukur seberapa besar nilai sebuah perusahaan.
Riwayat kapitalisasi pasar Invivyd, Inc. dari 2021 hingga 2026
IVVD dibandingkan dengan 5 teratas stocks paling populer
| Harga IVVD |
|
Aset B |
Pasar B |
Hasil |
|
|
|
|
$5.325T
|
+2,070,162.74%
|
|
|
|
|
$4.779T
|
+1,857,863.32%
|
|
|
|
|
$4.017T
|
+1,561,668.01%
|
|
|
|
|
$3.719T
|
+1,446,022.26%
|
|
|
|
|
$2.734T
|
+1,063,012.63%
|
